Authors
Latest:
Successful treatment of bilateral diffuse Uveal melanocytic proliueration with plasmapheresisNonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.
Latest:
Ultra-widefield imaging: A critical step in uveitis diagnosis and managementA multifaceted evaluation that includes ultra-widefield imaging can reveal new information and influence treatment decisions.
Latest:
Q&A: The increasing potential of ERG in diagnosing a wide range of eye conditionsEasier, more accessible functional studies have been made possible
Latest:
Humanity + technology: Talking to patients about the science and benefits of clinical trialsWhen we discuss trial participation with patients, we stress that the goal of these studies is to obtain better visual outcomes and ease the treatment burden.
Latest:
The unique role of the retina optometristZhang’s journey as the first retina optometrist in Colorado
Latest:
COVID-19 pandemic highlights the power of electronic health recordsElectronic health records may be the future of practice management.
Latest:
European Medicines Agency approves faricimab (Vabysmo) 6.0 mg single-dose prefilled syringeThe PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion.
Latest:
eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosaThe company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.
Latest:
High-resolution multimodal imaging is key in dry AMD therapeutic development, future managementIn an attempt to halt the progression of dry AMD and geographic atrophy, the use of high-resolution optical coherence tomography becomes pivotal.
Latest:
Effectiveness Of Pegcetacoplan In Preserving Visual Function In Geographic AtrophyDr Charles Wykoff presents the results of a post hoc microperimetry analysis from the OAKS study demonstrating the effectiveness of pegcetacoplan in preserving visual function.
Latest:
Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomesNeovascular macular degeneration is multifactorial, which requires future agents to target multiple pathways.
Latest:
AAO 2024: Bonnie An Henderson, MD, explores future of medical education in Kelman LectureHenderson’s presentation touches on the shift in medical education from traditional learning to AI and robotics.
Latest:
Clinical Implications of Port Delivery System in Retinal DiseasesClosing out his discussion on the port delivery system in retinal diseases, Chirag Jhaveri, MD, considers how this approach has impacted the treatment landscape.
Latest:
Vitrectomy: Is higher speed always better?Physicians should consider hydrodynamic cavitation when performing this procedure.
Latest:
Poll: Most anticipated emerging therapies in neovascular AMD and DMEA panel of retina specialists review new and emerging treatments in neovascular AMD and DME, highlighting high-dose aflibercept and KSI-301. Which emerging treatments are you most interested in?
Latest:
Pearls for maintaining quality, safety in retina clinics amid a pandemicTo maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimize clinic visits and maximize the use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximizing safety and patients’ vision outcomes.
Latest:
Case 2: Management of Progressive Geographic Atrophy in an 84-Year-Old ManFerhina S. Ali, MD, MPH, discusses the management of progressive geographic atrophy in an 84-year-old man, focusing on the significance of patient education in optimizing treatment outcomes and adherence.
Latest:
Regeneron announces aflibercept 8mg injection meets primary endpoint in phase 3 QUASAR trial in patients with retinal vein occlusionQUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared to EYLEA, in patients with RVO, including those with central, branch and hemiretinal vein occlusions.
Latest:
Setting a New Standard in Automated Tracked PerimetryInnovative new features build on the benefits of the iCare COMPASS Automated Perimeter
Latest:
OSN New York Retina 2024: Understanding how next-generation anti-VEGFs perform in real-world settings compared to trialsFerhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.
Latest:
A case of a 79-year-old pseudophakic patient with AMD and rapidly progressing GAThe final case is presented by Dr Adam, showcasing a 79-year old patient with multiple diagnoses and rapid progression of geographic atrophy.
Latest:
OSN New York Retina 2024: Understanding how next-generation anti-VEGFs perform in real-world settings compared to trialsFerhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.
Latest:
Ophthalmologist shares his story on Holocaust Remembrance DayJohn H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his story.
Latest:
Searching for durable therapies for diabetic macular edema amid the pandemicPatients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.
Latest:
Optimizing Care For Patients With Retinal DisordersKey takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.
Latest:
Exploring cryopreserved amniotic membrane following intravitreal injectionCAM encourages corneal healing in patients with ocular surface disease.
Latest:
Sustained-release anti-inflammatory therapy is valuable in noninfectious uveitisLong-term sustained-release therapy pays off in management of chronic, vision-threatening disease.
